Providing a VOICE for Montana's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2015
Meetings & Education
State & Federal Resources
National Professional Organizations
Off-Label Use Literature
Patient Advocacy Organizations
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
FDA granted this application priority review and zanubrutinib received orphan product and breakthrough therapy designations for treatment of MCL.
Read FDA announcement